GeneBioTech Ltd Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
GeneBioTech has a total shareholder equity of ₩49.4B and total debt of ₩15.6B, which brings its debt-to-equity ratio to 31.7%. Its total assets and total liabilities are ₩70.5B and ₩21.1B respectively. GeneBioTech's EBIT is ₩3.4B making its interest coverage ratio -22.6. It has cash and short-term investments of ₩23.4B.
Anahtar bilgiler
31.7%
Borç/özkaynak oranı
₩15.64b
Borç
| Faiz karşılama oranı | -22.6x |
| Nakit | ₩23.37b |
| Eşitlik | ₩49.42b |
| Toplam yükümlülükler | ₩21.05b |
| Toplam varlıklar | ₩70.47b |
Son finansal sağlık güncellemeleri
Here's Why Genebiotech (KOSDAQ:086060) Has A Meaningful Debt Burden
Feb 17
Is Genebiotech (KOSDAQ:086060) A Risky Investment?
Nov 19Recent updates
Market Cool On GeneBioTech Co. ,Ltd's (KOSDAQ:086060) Earnings
Aug 12
We Like The Quality Of GeneBioTech Ltd's (KOSDAQ:086060) Earnings
Mar 22Read This Before Buying GeneBioTech Co. ,Ltd (KOSDAQ:086060) For Its Dividend
Apr 15Should GeneBioTech Ltd (KOSDAQ:086060) Be Disappointed With Their 90% Profit?
Mar 18Here's Why Genebiotech (KOSDAQ:086060) Has A Meaningful Debt Burden
Feb 17How Does Genebiotech Co., Ltd. (KOSDAQ:086060) Fare As A Dividend Stock?
Jan 10Is Genebiotech (KOSDAQ:086060) A Risky Investment?
Nov 19Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: A086060's short term assets (₩54.6B) exceed its short term liabilities (₩18.7B).
Uzun Vadeli Yükümlülükler: A086060's short term assets (₩54.6B) exceed its long term liabilities (₩2.4B).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: A086060 has more cash than its total debt.
Borcun Azaltılması: A086060's debt to equity ratio has reduced from 43.6% to 31.7% over the past 5 years.
Borç Kapsamı: A086060's debt is not well covered by operating cash flow (13.2%).
Faiz Kapsamı: A086060 earns more interest than it pays, so coverage of interest payments is not a concern.